Edition:
United Kingdom

Innate Pharma SA (IPH.PA)

IPH.PA on Paris Stock Exchange

5.53EUR
9:39am GMT
Change (% chg)

€-0.01 (-0.18%)
Prev Close
€5.53
Open
€5.57
Day's High
€5.57
Day's Low
€5.43
Volume
46,564
Avg. Vol
415,479
52-wk High
€12.89
52-wk Low
€4.33

Chart for

About

Innate Pharma SA is a France-based biopharmaceutical Company that develops drugs for treatment of cancer and inflammatory diseases. The Company identifies and characterizes drug candidates, selects indications and manages the pre-clinical and clinical development of products. Innate Pharma primarily focuses on the development of... (more)

Overall

Beta: 1.11
Market Cap(Mil.): €603.39
Shares Outstanding(Mil.): 57.36
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 83.93 16.60
EPS (TTM): -- -- --
ROI: -- 1.66 10.66
ROE: -- 2.58 14.30

BRIEF-Innate Pharma Appoints Jean-Yves Blay To Its Supervisory Board

* INNATE PHARMA SA - JEAN-YVES BLAY APPOINTED TO INNATE PHARMA SUPERVISORY BOARD Source text for Eikon: Further company coverage: (Gdynia Newsroom)

31 Jan 2018

BRIEF-Innate Pharma And Medimmune Enter Clinical Trial Collaboration

* INNATE PHARMA AND MEDIMMUNE ENTER CLINICAL TRIAL COLLABORATION

30 Jan 2018

BRIEF-Eric Vivier Joins Innate Pharma As Chief Scientific Officer

* REG-WORLD RENOWNED IMMUNOLOGIST, PROFESSOR ERIC VIVIER, JOINS INNATE PHARMA AS CHIEF SCIENTIFIC OFFICER Source text for Eikon: Further company coverage: (Gdynia Newsroom)

08 Jan 2018

BRIEF-Innate Pharma provides an update on lirilumab

* ‍LIRILUMAB CONTINUES TO BE WELL-TOLERATED IN MONOTHERAPY AND IN COMBINATION ACROSS MULTIPLE TUMOR INDICATIONS

22 Nov 2017

BRIEF-Innate Pharma Q3 revenue up at 12.4 million euros

* Q3 REVENUE EUR 12.4 MILLION VERSUS EUR 11.2 MILLION YEAR AGO

15 Nov 2017

BRIEF-Innate Pharma reports IPH4102 final results of the dose-escalation part of the phase I study

* IPH4102: FINAL RESULTS OF THE DOSE-ESCALATION PART OF THE PHASE I STUDY

16 Oct 2017

BRIEF-Innate Pharma H1 operating loss widens to 18.2 million euros

* ‍CASH, CASH EQUIVALENTS AND FINANCIAL ASSETS() FOR COMPANY AMOUNTED TO EUR 204.1M (MILLION EUROS) AS OF JUNE 30, 2017​

18 Sep 2017

BRIEF-New preclinical data further strengthen rationale of IPH5401 and Monalizumab

* REG-INNATE PHARMA : NEW PRECLINICAL DATA FURTHER STRENGTHEN THE RATIONALE OF IPH5401 AND MONALIZUMAB

11 Sep 2017

Earnings vs. Estimates